The MOPETT Trial took sub-massive PE patients and randomized them to half-dose tPA vs. standard care. No bleeds in either group. 41% ARR of pulmonary hypertension at 28 months.
Study Description from the Author
Does this change your game?
A new trial using a similar protocol showed benefit without complications (Clinical Cardiology Volume 37, Issue 2, pages 78–82, February 2014)
Latest posts by Scott Weingart (see all)
- Presentation Mastery from the Teaching Course NYC 2015 - February 5, 2016
- Podcast 166 – Endocarditis with David Carr - January 25, 2016
- 2016 Essentials of Emergency Medicine Fellowship Competition - January 6, 2016